Milestone Pharmaceuticals Bolsters Board with New Directors
Company Announcements

Milestone Pharmaceuticals Bolsters Board with New Directors

Story Highlights

Milestone Pharmaceuticals (MIST) has released an update.

Milestone Pharmaceuticals has announced the appointment of two new independent directors, Stuart Duty and Andrew Saik, to its Board of Directors, with a third to be appointed soon. This move comes as the company, known for developing innovative cardiovascular medicines, enters an exciting period. Additionally, current directors Debra K. Liebert and Richard C. Pasternak will not seek reelection at the upcoming Annual Meeting.

For further insights into MIST stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyMilestone partner announces Phase 3 study of etripamil met primary endpoint
TipRanks Auto-Generated NewsdeskMilestone Pharmaceuticals Welcomes New Directors and Auditor
TheFlyMilestone Pharmaceuticals appoints Joseph Papa to board of directors
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App